KR101361531B1 - Composition for preventing and treating cancer - Google Patents

Abstract

The present invention relates to an anticancer composition, and more particularly, to the development of a functional natural product extract anticancer agent for anticancer adjuvant therapy and colon cancer prevention using anti-cancer properties of corilaginous gastrointestinal tumors, particularly colon cancer.

Description

Anticancer and anticancer adjuvant composition

The present invention relates to an anticancer composition, and more particularly, to the development of a functional natural product extract anticancer agent for anticancer adjuvant therapy and colon cancer prevention using anti-cancer properties of corilaginous gastrointestinal tumors, particularly colon cancer.

Representative cancer treatments of modern medicine include surgical surgery, biotherapy, radiation therapy, and chemotherapy with chemotherapy. Chemotherapy is a method of inhibiting the proliferation of cancer cells by administering oral or injecting an anticancer agent, the advantage of chemotherapy is that the drug can reach any cancer in any part of the body, and can treat metastatic cancer, Chemotherapy is currently used as a standard therapy for treating metastatic cancer. Of course, chemotherapy can not cure cancer, but it plays an important role in relieving symptoms and extending lifespan.

To date, the most widely used anticancer agent among natural anticancer agents is taxol, which is used to treat breast and ovarian cancers. However, these chemotherapeutic agents have problems such as side effects, anticancer drug resistance, and despite many studies on cancer until now, due to the diversity of cancer itself and diversification of pathogenesis mechanism, the side effects are small and can overcome the resistance. No cancer drugs have been developed.

Corilagin is a kind of gallotannin, which is an extract of natural vegetation (e.g., honey plant, Alchornea glandulosa), and gallotan is a type of gallic acid (gallic acid), a polyphenol monomer. It is a polymer formed by esterification and binding to the hydroxyl group of a polyol hydrocarbohyrate such as glucose. (Fig. 1) As a water-soluble extract of Korean native plant pearl pearl (fox bead, Phyllanthus urinaria). Sometimes it is extracted.

The present invention solves the above problems and the object of the present invention is to provide a natural-derived anticancer composition.

Another object of the present invention is to provide an adjuvant anticancer agent having a synergistic effect with an anticancer therapy using a conventional chemical anticancer agent.

In order to achieve the above object, the present invention provides a pharmaceutical composition for preventing or treating colorectal cancer, comprising corilagin as an active ingredient.

In another aspect, the present invention provides a pharmaceutical composition for preventing or treating colorectal cancer comprising the pearl extract as an active ingredient.

In another aspect, the present invention provides a pharmaceutical composition for anticancer supplement containing corilagin as an active ingredient.

In another aspect, the present invention provides a pharmaceutical composition for anticancer auxiliary containing pearl vinegar extract as an active ingredient.

Hereinafter, the present invention will be described.

The inventors of the present invention, while experimenting with the extract powder of phyllanthus urinaria, which was developed and used as a health functional agent for the treatment of chronic hepatitis B patients due to chronic HBV infection, accidentally water-soluble natural extract It has been found to induce apoptosis in cancer, gastric and hepatocellular carcinoma cell lines. Based on these observations, water-soluble extracts of pearl vinegar were analyzed by HPLC, and corilagin and brevifolin carboxylic acid anthocyanin were found to be the main component analysis. Focusing on gin, we compared and analyzed the interaction and anticancer capacity between 5-Fluorouracil (5-FU), an anticancer ability against gastrointestinal tumors (colon cancer, gastric cancer, and hepatocellular carcinoma) and its anticancer mechanism. Was studied.

The present invention is a water-soluble extract of natural plants, anti-cancer effect and chemical cancer prevention (chemoprevention) against the gastrointestinal tumors (colon cancer, gastric cancer, hepatocellular carcinoma) of Corilagin, a kind of gallotannin belonging to the water-soluble tannin family It is about the development of functional (medicinal) products of natural plants to prove the effectiveness and to be able to use the combination of the main treatment of the disease, or combination therapy or prophylaxis, in patients with high risk of carcinogenesis.

The present invention relates to the development of natural anticancer drugs based on corilagin, a kind of water-soluble gallotanin (gallotanin) extracted from natural plants, and particularly, colorectal cancer, gastric cancer, stomach cancer, and hepatocellular carcinoma ( In the treatment and prevention of hepatocellular carcinoma, the anti-cancer agent of coryazine is an anti-cancer agent with synergistic effects with conventional chemical anti-cancer agents, as well as an anti-cancer agent that shows synergistic effects. (chemopreventive agent) development.

Coryazine compounds included in the compositions of the present invention may also be used in the form of their salts, which include acid addition salts with various organic or inorganic acids that are pharmaceutically or physiologically acceptable. Suitable inorganic acids include, for example, hydrochloric acid, halogen acids such as sulfuric acid, and phosphoric acid. Suitable organic acids include, for example, carboxylic acid, phosphonic acid, sulfonic acid, acetic acid, propionic acid, octanoic acid, decanoic acid, glycolic acid, lactic acid, fumaric acid, succinic acid, adipic acid, malic acid, tartaric acid, citric acid, glutamic acid, aspartic acid. , Maleic acid, benzoic acid, salicylic acid, phthalic acid, phenylacetic acid, benzenesulfonic acid, 2-naphthalenesulfonic acid, methyl sulfuric acid, ethyl sulfuric acid, dodecyl sulfate.

The composition of the present invention may further comprise a coryazine compound, or a pharmacologically or physiologically acceptable carrier, excipient, diluent, in addition to the compound.

The composition of the present invention may be formulated in various forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, oral formulations, sterile injectable solutions, etc. It may be used and may be administered via a variety of routes including oral administration, intravenous, intraperitoneal, subcutaneous, rectal, topical administration and the like. Examples of suitable carriers, excipients and diluents that may be included in such a composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, Methylcellulose, amorphous cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil. The composition may further include a filler, an anti-coagulant, a lubricant, a wetting agent, a flavoring agent, an emulsifying agent, an antiseptic, and the like.

Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose, lactose, gelatin and the like in the composition. Mix and formulate. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used.

Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, preservatives, etc., in addition to commonly used simple diluents such as water and liquid paraffin.

Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Base materials for injections may include conventional additives such as solubilizers, isotonic agents, suspending agents, emulsifying agents, stabilizers, and preservatives.

In the present invention, "administration" means providing a predetermined substance to a patient in any suitable manner, and the administration route of the composition of the present invention may be oral or parenteral ≪ / RTI > In addition, the composition may be administered by any device in which the active agent may migrate to the target cell.

In the present invention, "patient" means a human and an animal such as a monkey, a dog, a goat, a pig, or a rat having a disease whose symptoms can be improved by administering the composition of the present invention. The compositions according to the present invention are applicable not only to humans (treatment, inhibition or prevention) but also to other commercially useful animals.

In another aspect, the present invention provides a method for inhibiting, preventing and treating cancer and cancer metastasis by administering to a patient a composition comprising a corylazine compound or a pharmaceutically acceptable salt thereof. The composition of the present invention can be administered in parallel with the above-mentioned conventional therapeutic agents for diseases.

The composition of the present invention is administered in a pharmaceutically effective amount.

In the present invention, "pharmaceutically effective amount" means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level will depend on the type of disease, severity, , Sensitivity to the drug, time of administration, route of administration and rate of release, duration of treatment, factors including co-administered drugs, and other factors well known in the medical arts. The composition of the present invention can be administered as an individual therapeutic agent or in combination with other therapeutic agents, and can be administered sequentially or simultaneously with conventional therapeutic agents, and can be administered singly or in multiple doses. It is important to take into account all of the above factors and to administer the amount in which the maximum effect can be obtained in a minimal amount without side effects, which can be easily determined by those skilled in the art.

Specifically, the effective amount of the compound according to the present invention may vary depending on the age, sex, and body weight of the patient. In general, 1 to 50 mg, preferably 1 to 10 mg, It may be administered one to three times a day.

However, the dosage may not be limited in any way because it may be increased or decreased depending on route of administration, severity of disease, sex, weight, age, and the like.

Corylazine compounds of the present invention can be isolated from natural materials or synthesized using methods well known in the art.

Hereinafter, the present invention will be described in detail.

In one embodiment of the present invention, it was confirmed whether coriligin exhibits anticancer ability against gastrointestinal tumors (colon cancer, gastric cancer, hepatocellular carcinoma),

In another embodiment, the degree of anticancer activity against gastrointestinal tumors (colon cancer, gastric cancer, hepatocellular carcinoma) was compared with that of 5-Fluorouracil (5-FU), an anticancer agent currently used.

In another embodiment to confirm that there is no synergy, interaction inhibition or interaction between the anticancer and 5-FU anticancer agents of corilagin,

In another embodiment, whether the mechanism of anti-proliferative ability of corilagin against gastrointestinal tumor (colon cancer, gastric cancer, hepatocellular carcinoma) cell line is due to cytotoxicity or ability to induce selective apoptosis. Confirmed.

The present invention was the first to discover that the treatment of corilagin in six types of gastrointestinal tumor (colon cancer, gastric cancer, hepatocellular carcinoma) cell line induces apoptosis. This anticancer effect was measured by MTT (3- (4,5-Dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide, a yellow tetrazole) method, which is a screening method for inhibiting cell proliferation by drugs (chronic B The dose-dependent inhibition of cell growth of the functional natural extract drug product used in the hepatitis kanji in the range of therapeutic dose to the human body was observed, especially in the case of colorectal cancer. (See Figures 2-4)

In addition, the present invention compared with the therapeutic effect of 5-Fluorouricil (5-FU), a representative anticancer agent used in the treatment of gastrointestinal tumors (colon cancer, gastric cancer, hepatocellular carcinoma) as a positive control, the therapeutic efficacy of the human therapeutic dose level A similar or effective result of 5-FU was obtained (see FIGS. 5 to 7).

After 5-FU treatment, MTT assay showed cell inhibition in proportion to concentration, but there was little change in cell inhibition at concentrations above 0.5ug / ml.

In addition, in order to investigate whether the anticancer capacity of gastrointestinal tumors (colon cancer, gastric cancer, hepatocellular carcinoma) is more effective than the negative control group, water-soluble red ginseng extract (commercially available product) used as a negative control group, and the water-soluble extract of Myeongil-yeop are treated. As a result, red ginseng and Myeongil-Yeop were treated, but did not show cell inhibition (see FIGS. 8 to 10).

In addition, the preparation of the present invention is a natural extract, a source natural product has been used for hundreds of years as a folk remedy, and recently it was recognized as a health functional drug and used for many years without problems, one of the main ingredients Incorylazine is a safe product that can be immediately used for preclinical and clinical studies.

In addition, in order to investigate whether the substance of the present invention is affected by acid and heat, hepat3B, a hepatocellular carcinoma cell line, was boiled or treated with corilagin, and showed growth resistance after treatment with acid and to some extent. To 16)

In addition, as a result of examining the anticancer adjuvant activity of the corilagin of the present invention, when treated with the corylazine at the same time than the 5-FU treatment alone, the growth rate of about 10 to 30% was further reduced. 21 to 28)

Gastrointestinal tumor in the present invention means colon cancer, stomach cancer, hepatocellular carcinoma malignant tumor,

Corilagin means gallotannin belonging to the water-soluble tannin family as one of the major constituent active ingredients of Jinjucho,

The MTT experiment refers to an experiment on cell proliferation inhibition using color reaction of 3- (4,5-dimethylmethylzol-2-yl) -2,5-diphenyltetrazolium bromide (a yellow tetrazole).

The present invention relates to the development of a natural anticancer drug based on corilagin, a water-soluble natural extract, which has a synergistic effect with corilagin in the treatment and prevention of gastrointestinal tumors, particularly colon cancer. In addition to the adjuvant anti-cancer agents indicated, there is an effect that can be used as a chemopreventive agent for cancer of the gastrointestinal tumor (colon cancer, stomach cancer, hepatocellular carcinoma) high risk group. The present invention can be used as an adjuvant anti-cancer agent that shows synergistic effects with existing treatments for colorectal cancer, etc. as a functional natural product anticancer agent that has been proved to be almost non-toxic, and a chemopreventive agent for cancer high risk groups such as colorectal cancer (chemopreventive) agent).

1 is a structure of a corilagin compound, gallotanine is a kind of polyphenol monomer (gallic acid) is esterified by the esterification (gallic acid) is combined with the hydroxyl group of the polyol hydrocarbohyrate (polyol hydrocarbohyrate) such as glucose (glucose) When the polymer is formed.
Figure 2 shows the growth rate when treated with corilagin in hepatocellular carcinoma cell line,
Figure 3 shows the growth rate when treated with corilagin (corilagin) in gastric cancer cell line,
Figure 4 shows the growth rate when treated with corilagin (corilagin) to colon cancer cell line,
Figure 5 shows the growth rate when treated with 5-FU in hepatocellular carcinoma cell line,
Figure 6 shows the growth rate when treated with 5-FU gastric cancer cell line,
Figure 7 shows the growth rate when treated with 5-FU colorectal cancer cell line,
8 shows the growth rate after treatment with natural products in hepatocellular carcinoma cell line,
Figure 9 shows the growth rate after natural product treatment in hepatocellular carcinoma cell line,
10 shows the growth rate after treatment with natural products in colorectal cancer cell lines,
Figure 11 shows the growth rate after treatment with boiled or acid-treated corilagin in HepG2, a hepatocellular carcinoma cell line,
Figure 12 shows the growth rate after treatment with boiled or acid-treated corilagin in HepG.2.152, a hepatocellular carcinoma cell line,
Figure 13 shows the growth rate after treatment with boiled or acid-treated corilagin in Huh7, a hepatocellular carcinoma cell line,
Figure 14 shows the growth rate after the treatment of boiled or acidic treatment of hepatocellular carcinoma cell line Hep3B,
Figure 15 shows the growth rate after treatment with boiled or acidic treatment of the corilagin in HT29 colon cancer cell line,
Figure 16 shows the growth rate after treatment with boiled or acid-treated corilagin in colon cancer cell line HTC116,
17 is a photograph comparing Western blot for Fas / FasLG (ligand) expression in hepatocellular carcinoma cell line Huh7, in which M is Marker, lane 1 is Huh7 Control, lane 2 is 5-FU 20ug / ml 24H, and lane 3 is Corilagin 100ug / ml 24H, lane 4 shows Huh7 Control, lane 5 shows 5-FU 20ug / ml 48H, and lane 6 shows Corilagin 100ug / ml 48H. As can be seen from the photograph, in the case of Huh7, Fas expression increase was not different from the control group, there was no Fas ligand (FasLG) expression. Thus, the Huh7 apoptosis mechanism is presumed to be due to a mechanism other than Fas / FasLG.
FIG. 18 is a photograph comparing Western blot for Fas / FasLG (ligand) expression in hepatocellular carcinoma cell line Hep3B, in which M is Marker, lane 1 Hep3B Control, lane 2 5-FU 20ug / ml 24H, lane 3 Corilagin 100ug / ml 24H, lane 4 shows Hep3B Control, lane 5 shows 5-FU 20ug / ml 48H, lane 6 shows Corilagin 100ug / ml 48H, and as shown in the photograph, in the case of Hep3B, Fas expression was increased. Was significantly increased in Corilagin-treated group compared to control and 5FU, and Fas ligand (FasLG) expression was also the same. Therefore, it is assumed that the Fas / FasLG mechanism is the most important for the Hep3B apoptosis mechanism.
19 is a photograph comparing Western blot for Fas / FasLG (ligand) expression in colorectal cancer cell line HT29, in which M is Marker, lane 1 is HT29 Control, lane 2 is 5-FU 20ug / ml 24H, and lane 3 is Corilagin 100ug / ml 24H, lane 4 shows HT29 Control, lane 5 shows 5-FU 20ug / ml 48H, lane 6 shows Corilagin 100ug / ml 48H, and as shown in the photograph, in the case of HT29, Fas expression was increased. The Corilagin group was significantly decreased compared to the control group and 5FU, and Fas ligand (FasLG) expression was also the same. Therefore, the mechanism of HT29 apoptosis other than Fas / FasLG mechanism is considered to be important.
20 is a photograph comparing Western blot for Fas / FasLG (ligand) expression in colorectal cancer cell line HCT116, in which M is Marker, 1 lane is HCT116 Control, 2 lane is 5-FU 20ug / ml 24H, and 3 lane is Corilagin 100ug / ml 24H, 4 lanes are HCT116 Control, 5 lanes are 5-FU 20ug / ml 48H, 6 lanes are Corilagin 100ug / ml 48H, As can be seen from the photo, in the case of HCT116, Fas expression increased state Corilagin-treated group showed increased tendency compared to control and 5FU, but Fas ligand (FasLG) expression was not observed. Therefore, HCT116 apoptosis mechanism is presumed to be involved in the mechanism other than Fas / FasLG.
FIG. 21 is a table and a graph showing the growth rate when 5-Fu and corilagin were simultaneously treated with HepG2, a hepatocellular carcinoma cell line. As can be seen from FIG. 21, the growth rate of about 5 to 10% was further increased when coryazine was simultaneously treated than when 5-FU was treated.
22 is a table and a graph showing the growth rate when 5-Fu and corilagin were co-treated with HepG2.2.15, a hepatocellular carcinoma cell line. As can be seen from Figure 22, when treated with the corylazine at the same time than the treatment with 5-FU further showed a further decrease of about 7% growth rate.
FIG. 23 is a table and a graph showing growth rates when 5-Fu and corilagin are simultaneously treated in Huh7, a hepatocellular carcinoma cell line. As can be seen from Figure 23, when treated with the same simultaneous treatment with coryazine than 5-FU only showed a further decrease in growth rate of about 20-30%.
FIG. 24 is a table and a graph showing the growth rate when hep3B7, a hepatocellular carcinoma cell line, simultaneously treated with 5-Fu and corilagin. As can be seen from FIG. 24, a further reduction in growth rate of about 15% was observed when corridazine was simultaneously treated than when 5-FU alone was treated.
FIG. 25 is a table and a graph showing growth rates when 5-Fu and corilagin were simultaneously treated in gastric cancer cell line MKN45. As can be seen from FIG. 25, the growth rate was further increased by about 15% when corylazine was simultaneously treated than when 5-FU was treated.
FIG. 26 is a table and a graph showing growth rates when 5-Fu and corilagin were simultaneously treated in AGS, a gastric cancer cell line. As can be seen from FIG. 26, AGS was more sensitive to growth rate inhibition to coryazine than other cell lines, and further reduced growth rate by about 15% when treatment with coryazine simultaneously than with 5-Fu alone. Seemed.
FIG. 27 is a table and a graph showing the growth rate when 5-Fu and corilagin were simultaneously treated with HCT116, a colorectal cancer cell line. As can be seen from FIG. 27, the growth rate was further increased by about 15% when corridazine was simultaneously treated than when 5-FU was treated alone.
FIG. 28 is a table and a graph showing the growth rate when 5-Fu and corilagin are simultaneously treated in HT29, a colorectal cancer cell line. As can be seen from Figure 28, when treated with the corylazine at the same time than the treatment with 5-FU further showed a further decrease in growth rate of about 5-10%.
FIG. 29 is a table and a graph showing the growth rate of corylazine treatment for two types of colorectal cancer cell lines (HCT116 and HT29) and non-tumor cells (UCMCS, umbilical cord-derived immature stem cells, not cancer cells) as a control group. .
Fig. 30 shows the growth rate when corylazine was treated for four types of hepatocellular carcinoma cells (HepG2, HepG2.2.15, Huh7, Hep3B) and non-tumor cells (UCMCS, immature stem cells, not cancer cells) as a control group. Tables and graphs for

The present invention will now be described in more detail by way of non-limiting examples. The following examples are intended to illustrate the invention and the scope of the invention is not to be construed as being limited by the following examples.

The cell lines used in the present invention obtained AGS- 21739, MKN-80103, Ht29-30038, Hct116-10247, Hepg2-88065, Huh7-60104, Hep3B-88064 from the Korea Cell Line Bank.

In addition, two cancer cell lines with different personalities were identified for each cancer cell (colon cancer, HT29-30038 / HCT116-10247, hepatocellular carcinoma, Huh7-60104 / Hep3B-88064; gastric cancer, AGS- 21739, / MKN- 80103; hepatoblasts). Cancer, HepG2-88065 / HepG2.2.15) each of the comparative study experiments were performed.

Reagents used in the present invention and where to buy is FBS (Gibco), antibiotic-antimycotic (Sigma), MTT (Sigma), corilagin (Santa cruz biotechnology).

Example  1: natural treatment

Myeongilyeop extract and 6 years old red ginseng extract of Jeonggwanjang were made into aqueous solution, filtered with 0.25um sylinge filter, and then treated to each cell line. The concentration was determined by converting the amount of human intake into 5000 ml serum once.

In addition, pearl leaf extract extracts the purchased pearl leaf, hepagard (Ilyang Pharmaceutical), which is a commercially available pearl leaf extract, is crushed, and then broken down, and then analyzed through three major peaks (brevifolin, Confirming that anthocyanin and corilagin were present in the same concentration, there was no difference in composition between the materials used in the two experiments, namely, the pearlescent raw extract and the water-soluble extract (dissolved in H2O) of the ground powder of Hepagard. It was used for the experiment. Corilagin powder was purchased commercially (Santa cruz biotechnology) and dissolved in DMSO and used in experiments as needed.

Example  2: MTT assay

Gastrointestinal tumor (colon cancer, gastric cancer, hepatocellular carcinoma) cell lines were seeded at 5 × 10 ³ cells / well in 96 wells and then cultured for 2 days. Pearl persimmon extract was treated by concentration, and treated as a control group by 5-Fu concentration and incubated for 48 hours. After treatment with 10ul of 5mg / ml MTT for 4 hours, the culture medium was removed, and 100ul of the solution mixed with isopropanol and DMSO at a ratio of 10: 1 was reacted for 15 minutes, and then absorbance was measured at 570nm / 640nm.

Example  3: cell culture

Culture medium and components for the cells used in the present invention are shown in Table 1.

HepG2 MEM 1% antibiotic 10% FBS 2.2.15 DMEM 1% antibiotic 10% FBS Hep3B DMEM 1% antibiotic 10% FBS Huh7 DMEM 1% antibiotic 10% FBS HT29 RPMI1640 1% antibiotic 10% FBS HCT116 RPMI1640 1% antibiotic 10% FBS AGS RPMI1640 1% antibiotic 10% FBS MKN45 RPMI1640 1% antibiotic 10% FBS

Table 1 shows the culture information for the cells used in the present invention.

DMEM of the present invention is 4500 mg / L D-glucose, L-glutamine, 110 mg / L sodium pyruvate

And Sodium Bicarbonate, and RPMI1640 contained 25 mM Hepes.

Example  4: Western Blot

Each cell line was inoculated with 1 × 10 ⁶ / well in a 6 well plate. After 48 hours incubation at 37 ℃ 5% CO 2 conditions to treat the reagents to see the reaction by concentration, incubated for 24, 48 hours. After removing the media of the plate, washed with PBS, cells were removed using trypsin-EDTA, centrifuged for 3 minutes at 1200rpm, pellets were collected in 1.5.ml tube after washing with PBS. 100 μl of RIPA buffer containing protease inhibitor cocktail was added to each tube and reacted for 10 minutes. Centrifuge for 15 minutes at 15000 rpm, and the supernatants were collected separately. Protein concentration was measured using a Bio-Rad protein assay and loaded on 10% SDS-PAGE Gel at 30ug / well. The separated protein was transferred to a nitrocellulose filter, blocked using skim milk, and the Primary Ab was reacted at 4 ° C. for 16 hours. After washing, the secondary Ab was reacted at room temperature for 2 hours, and then developed by using an X-ray film after exposure to ECL solution for 1 minute.

Example  5: in normal cells and cancer cells Of corilagin  Compare effects

The UCMCS cell line used in the present invention is immature stem cells derived from umbilical cord cells, which are differentiated from normal umbilical cord cells, and are not cancer cells. In this embodiment, corylgin (Corilagin) is applied to colon cancer cell lines (2 types) and liver cancer cell lines (2 types). , Santa cruz biotechnology) was used as a control for the anticancer MTT experiment.

In summary, each cell line is seeded at 5 × 10 ³ cell / well in 96 wells and incubated for 2 days. Corylazine was treated by concentration, and 5-FU was treated by concentration as a control, followed by incubation for 48 Hr. After 10ul of 5mg / ml MTT was treated for 4hr, the culture medium was removed, and 100ul of the solution mixed with isopropanol and DMSO at a ratio of 10: 1 was reacted for 15 minutes, and then absorbance was measured at 570nm / 640nm.

As can be seen in FIGS. 29 and 30, corylazine showed proliferation inhibition for two colon cancer cell lines and four hepatocellular carcinoma cell lines with increasing concentration, but no inhibitory effect for UCMCS cell lines. There was no.

Claims (8)

A pharmaceutical composition for preventing or treating colorectal cancer, comprising corilagin as an active ingredient. delete An anticancer pharmaceutical composition for colorectal cancer or stomach cancer containing corilagin as an active ingredient. delete delete delete delete delete

Images